Savings and support
for your patients

Eligible patients can pay as little as $15* per fill

Motegrity savings card

Encourage your patients to sign up for a Motegrity Savings Card

With the Motegrity Savings Card, eligible patients can pay as little as $15* for each 30-day prescription fill of Motegrity. This offer is valid for up to 15 uses, or until the program expires.

*Up to $90 max benefit per 30-day prescription. See below for Terms and Conditions.

Register for Savings Card

Terms & Conditions

Eligible Commercially Insured patients may pay as little as [$15] and receive up to [$90] off their co-pay or out of pocket expenses per 30 day supply of Motegrity™ (prucalopride). Offer valid for up to [15] uses through offer expiry. A valid Prescriber ID# is required on the prescription. Offer valid for patients ages 18 and older. [Offer not valid for cash paying patients.]

Restrictions: This offer is only valid for residents of the United States, Puerto Rico and U.S. Territories. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare, or other federal or state health programs (including any state medical assistance program) or where prohibited by the health insurance provider. Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer. Offer not valid for patients under 18 years of age. It is illegal to (or offer to) sell, purchase, or trade this offer. Program expires [12/31/2019]. If your insurance situation changes, it is your responsibility to notify [customer service at 1-833-666-2499]. This offer is not transferable and is limited to one offer per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer. Not valid if reproduced. Void where prohibited by law. Program managed by ConnectiveRx on behalf of Shire US Inc. The parties reserve the right to discontinue, rescind, revoke or amend this offer without notice at any time. This is not health insurance.

Coverage questions?
Contact Motegrity Answers

Call 1-844-447-2582 for assistance

Get answers about Motegrity, including:

  • Savings program
  • Benefits investigation
  • Prior authorization

Motegrity Answers is available Monday through Friday from 8 a.m. to 8 p.m. ET

Briefcase Icon

Request a Rep Visit

Submit a request to speak
with a Takeda representative

Submit Request
Bottle Icon

Request Samples

Interested in receiving
samples of Motegrity?

Request Samples
Previous Page Dosing & Administration
Arrow

IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for persistent worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if their depression is persistently worse, or they experience emerging suicidal thoughts or behaviors.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis

Indication

Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for persistent worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if their depression is persistently worse, or they experience emerging suicidal thoughts or behaviors.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis

Indication

Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.

Continue

Study Design details1

In Studies 2 and 6, geriatric patients (≥65 years) started at 1 mg of Motegrity once daily and, if necessary, the dose was increased to Motegrity 2 mg after 2 or 4 weeks of treatment if response was insufficient at 1 mg. Of these patients, 81% (n=93/115) increased to 2 mg.1

Inclusion Criteria1
  • History of chronic constipation defined as having <3 SBMs per week that resulted in a feeling of complete evacuation (complete spontaneous bowel movement; CSBM)
  • 1 or more of the following symptoms for >25% of BMs in the preceding 3 months, with symptoms onset >6 months prior to screening:
    • Lumpy or hard stool
    • Sensation of incomplete evacuation
    • Straining at defecation
  • Patients who never had SBMs were eligible
  • In Study 1, eligibility also included sensation of ano-rectal obstruction or blockade or the need for digital manipulation in more than 25% of BMs
Exclusion Criteria1
  • Constipation was due to secondary causes
  • Suspected drug-induced constipation

BM=bowel movement; SBM=spontaneous bowel movement

Reference:
1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Shire LLC.

Key patient demographics & baseline characteristics1,2*

Study design infographic Study design infographic

*Characteristics for placebo and Motegrity ≤2 mg groups. For more demographics and baseline characteristics see Camilleri et al. 2016.
BMI=body mass index; SBM=spontaneous bowel movement

References:
1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Shire LLC. 2. Camilleri M, Piessevaux H, Yiannakou Y, et al. Dig Dis Sci. 2016;61(8):2357-2372.

Alternative Endpoint Study Results1

Efficacy responder rates in placebo-controlled studies of CIC: Proportion of patients with an average of ≥3 CSBMs/week and an increase of ≥1 CSBM/week for at least 9 out of the 12 weeks, including 3 of the last 4 weeks (ITT population)1

Study Motegrity
1 or 2 mg Once Daily		 placebo Treatment Difference
N n (%) N n (%) (95% CI)
Study 1 249 65 (26) 252 22 (9) 17 (11, 24)
Study 2 177 57 (32) 181 25 (14) 18 (10, 27)
Study 3 236 30 (13) 240 13 (5) 8 (2, 12)
Study 4 190 37 (19) 193 15 (8) 11 (5, 18)
Study 5 214 34 (16) 212 11 (5) 11 (5, 16)
Study 6 171 29 (17) 169 22 (13) 4 (-4, 12)

CSBM=complete spontaneous bowel movement; N=number of patients per treatment group; n=number of responders

Select Important Safety Information

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Reference:
1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Shire LLC.

You are being directed to another website.

Cancel Continue

By following this link you will be leaving a Takeda controlled website for a third party website.

Please note that Takeda is not responsible or liable for any third party website and the website may not be appropriate for all audiences.

Cancel Continue